SynthesisBMC gastroenterology2026
"The role of red cell distribution width in inflammatory bowel disease evaluation: a comprehensive systematic review and meta-analysis".
Synthesis in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory markers are routinely used in the evaluation of inflammatory bowel disease (IBD). Red blood cell distribution width (RDW) has previously been proposed as a potential biomarker in the evaluation of IBD. This meta-analysis and systematic review challenges the utility of RDW in IBD evaluation.
methodsWe conducted a systematic review and meta-analysis following PRISMA guidelines. A search strategy was formulated based on Medical Subject Headings (MeSH) terms and other relevant medical terms. A comprehensive search of PubMed, Web of Science, and Scopus was performed up to 4th of September 2025. Data were extracted for identifying the role of RDW in IBD detection and its association with disease activity. Statistical analysis employed a random-effects model, with subgroup analysis performed according to different levels of disease activity.
resultsRDW was significantly elevated in patients suffering from Crohn's disease (CD) (MD = 2.2, p < 0.001) and ulcerative colitis (UC) (MD = 1.36, p < 0.001) compared to healthy controls. Both diseases showed significantly higher RDW in active disease versus remission (CD: MD = 1.29, p < 0.001; UC: MD = 1.11%, p < 0.001). For differentiating active CD from remission, an RDW cut-off > 14% showed a sensitivity of 0.86 and specificity of 0.78 (AUC = 0.83). RDW levels were also significantly higher in active CD compared to active UC (MD = 0.59, p < 0.005).
conclusionRDW levels were markedly increased in patients with IBD compared to healthy controls. Furthermore, RDW showed a consistent association with both disease activity and severity. Given its wide availability, low cost, and reliable diagnostic performance, RDW could represent a practical and valuable biomarker for evaluating inflammatory bowel disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.